Interleukin-13 receptor pathway (IL-13 pathway)

The **Interleukin-13 pathway** comprises the signaling events initiated by the cytokine Interleukin-13 (IL-13), an immune mediator primarily produced by Th2 lymphocytes, mast cells, basophils, and eosinophils[4][7]. IL-13 binds to its receptors, mainly **Interleukin-13 receptor alpha 1 (IL-13Rα1)** and **Interleukin-13 receptor alpha 2 (IL-13Rα2)**, on a variety of cell types. The principal functional complex is formed by the sequential binding of IL-13 to IL-13Rα1, which then associates with IL-4Rα to generate the active Type II receptor, leading to activation of the STAT6 transcription factor and immune effector functions[2][7]. This pathway orchestrates allergic inflammation, mucus hyperproduction, airway hyperresponsiveness, IgE synthesis, and the recruitment and activation of inflammatory cells. It also participates in tissue remodeling via induction of matrix metalloproteinases and is implicated in several diseases: asthma, atopic dermatitis, fibrosis, allergic rhinitis, and certain cancers. In recent years, IL-13 and its receptors have also been recognized as regulators in the central nervous system, modulating synaptic plasticity and neuronal survival[3]. Therapeutically, the IL-13 pathway is targeted by monoclonal antibodies (e.g., tralokinumab, lebrikizumab, dupilumab), which block IL-13 itself or the receptor subunits, attenuating pathologic Th2-type inflammation. Biomarkers for treatment monitoring include serum IL-13, periostin, and eosinophil counts. Key safety concerns for pathway inhibition include increased infection risk and possible interference with physiologic repair mechanisms. As a "pathway," this entry refers to a network of targets rather than a single molecule, and for drug targeting or biological research, more specific identification (such as "Interleukin-13 receptor alpha 1") is necessary[7][1][2][3][4].

Other names

IL-13 signaling pathwayInterleukin-13 signaling cascadeType II IL-4 receptor signaling pathway (context-dependent)IL-13/IL-4 shared pathway

Neutralization of IL-13: Monoclonal antibodies bind and neutralize Interleukin-13, preventing receptor interaction. Receptor blockade: Antibodies prevent IL-13 from engaging its receptor, particularly IL-13Rα1, thereby inhibiting downstream signaling. Dual IL-4/IL-13 inhibition: Dupilumab blocks IL-4Rα, inhibiting both IL-4 and IL-13 mediated signaling[7].